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Background: Several case series and small randomized controlled trials suggest that therapeutic plasma exchange
(TPE) improves coagulation, hemodynamics and possibly survival in severe sepsis. However, the exact role of TPE in
modern sepsis therapy remains unclear.
Methods: We performed a retrospective observational single-centre study on the use of TPE as rescue therapy in
23 consecutive patients with severe sepsis or septic shock from 2005 to 2012. Main surrogate markers of multiple
organ failure (MOF) before, during and after TPE as well as survival rates are reported.
Results: At baseline, mean SOFA score was 13 (standard deviation [SD] 4) and median number of failed organ-systems
was 5 (interquartile range [IQR] 4–5). TPEs were performed 3 days (IQR 2–10) after symptom onset and 1 day (IQR 0–8)
after ICU admission. The median total exchange volume was 3750 ml (IQR 2500–6000), which corresponded to a
mean of 1.5 times (SD 0.9) the individual plasma volume. Fresh frozen plasma was used in all but one treatments as
replacement fluid. Net fluid balance decreased significantly within 12 hrs following the first TPE procedure by a median
of 720 mL (p = 0.002), irrespective of outcome. Reductions of norepinephrine dose and improvement in cardiac index
were observed in individual survivors, but this was not significant for the overall cohort (p = 0.574). Platelet counts
decreased irrespective of outcome between days 0 and 2 (p < 0.003), and increased thereafter in many survivors.
There was a non-significant trend towards younger age and higher procalcitonin levels among survivors. Nine out of
23 TPE treated patients (39%) survived until ICU discharge (among them 3 patients with baseline SOFA scores of 15,
17, and 20).
Conclusions: Our data suggest that some patients with severe sepsis and septic shock may experience hemodynamic
stabilisation by early TPE therapy.
Keywords: Multiorgan dysfunction syndrome, Multiple organ failure, Apheresis, Plasmapheresis, Streptococcal toxic
shock syndromeBackground
Sepsis is the most common cause of death in medical in-
tensive care units and the 10th most common cause of
death in the United States. The incidence of sepsis has
increased over the last two decades with an unchanged
mortality rate of approximately 30% for severe sepsis [1]
and 40 to 70% for septic shock [2,3]. With withdrawal of* Correspondence: hadem.johannes@mh-hannover.de
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reproduction in any medium, provided the oractivated protein C from the market in 2011, the last ap-
proved specific pharmacological intervention for sepsis
(aside from antibiotic therapy) was removed from our
armentarium, and further treatment modalities are des-
perately needed. This seems particularly true for the
early phase of sepsis where patients are often over-
whelmed by a “cytokine storm”.
Sepsis is triggered by exogeneous microbial exposure –
so-called pathogen-associated molecular patterns (PAMPs).
PAMPs are recognized by pattern-recognition receptors on
polymorphonuclear leukocytes and macrophages whichLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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of cytokines and chemokines, and other proinflammatory
mediators [4]. In some cases, the innate immune activation
to PAMPs is de-regulated, converting responses that are
normally beneficial for fighting infections into excessive
damaging inflammation [5]. In addition, certain bacteria
such as group A streptococci secrete molecules that down
regulate the ability of the host to eliminate bacteria besides
other molecules that reduce phagocytic properties or those
that activate coagulation [6,7]. The rationale for the use of
therapeutic plasma exchange (TPE), a non-selective inter-
vention, is to remove multiple toxic mediators including
endotoxins, proinflammatory cytokines and procoagulant
factors. Furthermore, depleted plasma factors involved in
the homeostasis of microcirculation are replenished by TPE
[8]. One such factor could be a disintegrin-like and metallo-
protease with thrombospondin type 1 repeats (ADAMTS)-
13 that regulates primary hemostasis by proteolyzing von
Willebrand factor and is possibly involved in disseminated
intravascular coagulation due to severe sepsis [9].
Only very limited data are available regarding TPE for
this indication. Two randomized controlled trials with a
total of 136 patients examined the impact of TPE on
outcome in severe sepsis and septic shock. A promising
survival benefit in TPE treated patients in the largest
randomized trial (106 patients) with a 28-day mortality
rate of 33% in the TPE group compared to 54% in the
control group did not remain significant after multiple
logistic regression analysis [10]. A smaller trial by Reeves
et al. demonstrated a trend towards ameliorated organ
failure but no significant difference in mortality [11]. A
number of observational studies investigated plasma ex-
change as rescue therapy in severe sepsis with varying
mainly descriptive results [12-24]. Thus, TPE has not yet
formed part of international sepsis guidelines [25]. A
recent expert consensus statement, however, advocated
that patients with refractory septic shock should be
considered for extracorporeal blood treatments [26].
Also the 2010 guidelines on the use of therapeutic
apheresis in clinical practice [27] list TPE as a 2B (weak
recommendation, moderate quality evidence) recom-
mendation in the treatment of sepsis, making the indi-
vidual clinical and laboratory course of patients along
with the available resources the foundation for TPE pre-
scription in sepsis.
In the present manuscript, we report our single-centre
experience with TPE as rescue therapy in 23 consecutive
patients admitted for severe sepsis or septic shock be-
tween 2005 and 2012.
Methods
We performed this retrospective observational single-
centre study in accordance with the ethical guidelines of
the 1975 Declaration of Helsinki. The Ethics Committeeof the Hannover Medical School waived the need for
ethical approval and informed patient consent, as i) data
acquisition was retrospective observational within our
clinic, ii) data were de-identified, and iii) the study relied
on measurements and rescue therapies applied as part of
routine care (enquiry #1651-2012).
Severe sepsis was defined by the presence of at least 2
out of 4 SIRS criteria plus suspected infection either by
clinical examination, radiological or mirobiological evi-
dence with at least one organ dysfunction. Septic shock
was defined as severe sepsis plus systolic arterial pres-
sure < 90 mm Hg or mean arterial pressure < 65 mm Hg
over at least 1 h and despite adequate volume resuscitation
[25]. None of the patients received hydroxyethylstarch.
All patients were treated based on an in-house protocol
adopting the standards recently summarized in the
German S-2 k guidelines [28]. Intravenous hydrocortisone
was given if adequate fluid resuscitation and vasopressor
therapy did not restore hemodynamic stability. Renal
replacement therapy was performed as extended hemo-
dialysis using the Genius® batch dialysis system as de-
scribed elsewhere [29]. TPE as a rescue therapy forms part
of our treatment standard in cases with progressive severe
sepsis not responding to conventional critical care after
weighing its benefits and risks on an individual patient
basis. Rescue TPE sessions were stopped either if conven-
tional therapeutic measures alone could effectively ensure
clinical stability or if progressive hemodynamic instability,
microcirculatory changes, and refractory lactic acidosis led
to an end-of-life discussion. We used both, membrane Gam-
bro PF 2000 (polypropylene, 0.4 m2; Gambro, Hechingen,
Germany) or the Plasmaflow OP by Asahi Medical Co.
(polyethylene, 0.5 m2; Tokyo, Japan) with Multifiltrate
(Fresenius Medical Care, Bad Homburg, Germany) and
Octo Nova (Diamed Medizintechnik, Cologne, Germany)
and centrifugal (Spectra Optia, Terumo BCT, Denver, CO,
USA) technology for the procedure. In every patient we
aimed for an exchange volume that equals 1.2 to 1.5 fold
of the individual plasma volume. Plasma volume was cal-
culated as follows: Estimated plasma volume (in liters) =
0.07 × weight (kg) × (1-hematocrit) [30]. Removed plasma
was substituted with fresh frozen plasma (FFP) in a 1:1
ratio in 22 patients. Only one patient (#10) received 20%
albumin diluted 1:4 with an electrolyte solution as replace-
ment fluid. Vascular access was obtained via an indwelling
double lumen catheter inserted in the internal jugular
vein. In one case TPE was performed over an extracorpor-
eal membrane oxygenation (ECMO) circuit.
Based on patient charts and TPE protocols, organ dys-
function at baseline, as well as during and after the first
TPE was assessed [25,31]. Discharge from intensive care
unit was the primary outcome. Secondary endpoints were
dose of vasopressors as a marker of hemodynamic stabil-
ity, reductions in net fluid balance as a marker of vascular
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nated intravascular coagulation (DIC). We also analyzed
need for renal replacement therapy, time from symptom
onset to TPE, time from ICU admission to TPE, TPE
interval, total number of TPEs performed, as well as ex-
changed plasma volumes in relation to individual plasma
volumes.
Descriptive statistical analysis was carried out with the
help of IBM Statistics software, version 21. Kolmogorov-
Smirnov test and Shapiro-Wilk test were performed to
prove or dismiss suspected normal data distribution.
Data were accordingly presented as means (standard de-
viation, SD), or medians (interquartile range, IQR).
Intra-individual changes of net fluid balances, noradren-
aline doses, and platelet counts before and after the first
TPE were compared by Friedman’s and Wilcoxon test.
Presumed parameter variances between survivors and
non-survivors were compared by Mann–Whitney-U test,
or Student’s T test. Exact Fisher’s test was used to ana-
lyse the frequency of occurrence of streptococcal sepsis
and immunosuppressive co-morbidities with respect to
outcome.
Results
Patients’ clinical baseline characteristics and risk factors
for acquisition of severe sepsis
We retrospectively identified 23 consecutive patients (14
males, 9 females) with a mean age of 42 years (SD 18) who
received TPE for severe sepsis or septic shock. Mean body
mass index was 23.5 kg/m2 (SD 3.8). Eighteen patients
(78%) were in septic shock, and 5 had a severe sepsis. The
focus of infection was pneumonia in 14, soft tissue infec-
tion in 3, colon perforation with peritonitis in 1, sinusitis
in 1, catheter-related in 1, and hepatitis in 1 patient. Two
patients had no identifiable infectious focus. Microorgan-
isms and viruses involved (co-infections possible) were
streptococci (44%), staphylococci (17%), enterobacteria-
ceae (13%), Pseudomonas (13%), H1N1-influenza (9%),
herpes-virus (9%), and adenovirus (4%). Eighteen patients
were at risk of infection due to underlying immunosup-
pressive therapy, and 5 patients developed severe sepsis
without any preceding sign of being immune-compromised
(Table 1).
Severity of multiple organ failure and outcome
The median number of organs that failed during the
ICU stay was 5 (IQR 4–5), mirrored by a mean baseline
SOFA score of 13 (SD 4). Only twelve patients (52%)
were ventilated on admission, however, 22 patients
(96%) needed mechanical ventilation and/or ECMO later
during the ICU stay. Median Glasgow coma scale of
non-ventilated patients at ICU admission was 14 (IQR
14–15). Norepinephrine was required by 21 (91%) dur-
ing the ICU stay, vasopressin/terlipressin by 7 (30%),dobutamine by 7 (30%), and levosimendan by 1 patient
(4%). Recombinant activated protein C was given to 3
patients (13%), and ECMO (veno-venous or in case of
severe cardiomyopathy veno-arterial) was instituted in 8
patients (35%). Baseline pO2/FiO2 was 108 mm Hg (IQR
83–240). Mean baseline creatinine was 221 μmol/l (SD
153). Twenty patients (87%) required renal replacement
therapy during their ICU stay. Nine out of 23 patients
(39%) survived until ICU discharge (Table 2).
Dose and adequacy of TPE
A median of 2 TPE therapies (IQR 1–3) were performed
and started 3 days (IQR 2–10) after symptom onset, i.e.
1 day (IQR 0–8) after ICU admission. Median total plasma
volume exchanged was 3750 mL (IQR 2500–6000), which
corresponded to 1.5 (SD 0.9) times the individual plasma
volume. All but one TPE therapies used FFP as replace-
ment fluid (median 15 units [IQR 10–24]). Anticoagula-
tion was ensured by heparin in 9 (39%), citrate in 9 (39%)
or absent in 5 patients (22%). 21 of 23 patients were
treated by membrane technique, 2 by centrifugal technique
(Table 3). In those 14 patients who died in the ICU, me-
dian time from termination of the first TPE and death was
48 h (IQR 29–162). Two patients (22%) survived to ICU
discharge in the heparin anticoagulation group, 5 patients
(56%) in the citrate group, and 2 patients (40%) in the no-
anticoagulation group.
Influence of TPE on catecholamine dose and net fluid
balance
Since mean blood pressures appeared stable during the
time periods of plasma exchange, we decided to monitor
norepinephrine dose and reduction of net fluid balance
compared to the preceding day as surrogate markers of
cardiovascular stability. The first TPE procedure neither
influenced overall norepinephrine doses (p = 0.574), nor
were norepinephrine doses around the first TPE associ-
ated with outcome (p > 0.20, Figure 1). However, impres-
sive reductions of norepinephrine doses were seen in
individual cases. One example is patient #4 who received
her first and only TPE on the day of admission, being as-
sociated with a 90% reduction of norepinephrine dose
within 24 hours. Another example is patient #6, who de-
veloped septic cardiomyopathy with low output syndrome
and temporary cardiac arrest on day 7 of her ICU stay but
improved substantially after TPE was intiated. In contrast,
reductions of net fluid balances by a mean of 720 mL
within 12 h following the first TPE were observed in the
majority of patients following the initial TPE session (p =
0.002), irrespective of outcome (p > 0.77) (Figure 2).
Effect of TPE on disseminated intravascular coagulation
Since fibrinogen, prothrombin time and activated partial
thromboplastin time are highly influenced by TPE, platelet
Table 1 Septic focus, associated pathogen(s) and risk factors for infection
Patient Septic focus and associated pathogen(s) Risk factors for infection
1 Septic shock (pneumonia, Staphylococcus aureus) Microscopic polyangiits, cryoglobulinemia, chronic renal disease
2 Severe sepsis (soft tissue infection, Streptococcus pyogenes) None
3 Septic shock Pancytopenia, cryoglobulinemia
4 Septic shock (perianal soft tissue infection, Streptococcus group A) Excision of an anal tag
5 Septic shock (pneumonia, Pseudomonas aeruginosa) UIP, Sjögren's syndrome, alveolitis, immune complex vasculitis
6 Septic shock (parastomal abscess, Peptostreptococcus, Candida) with
septic or Infliximab-associated cardiomyopathy
Crohn's disease with anal and parastomal fistulas
7 Septic shock (pneumonia, Streptococcus pneumoniae) Post splenectomy
8 Septic shock (pneumonia, Escherichia coli) None
9 Septic shock Crohn's disease, short bowel syndrome
10 Severe sepsis (rhabdomyolysis and pneumonia, Adenovirus,
Streptococcus pneumoniae, Staphylococcus aureus)
None
11 Severe sepsis (pneumonia, H1N1) with VAHS Type 2 Diabetes, obesity hypoventilation syndrome
12 Septic shock (pneumonia, Staphylococcus haemolyticus, Candida krusei) MDS with pancytopenia
13 Severe sepsis (pneumonia, H1N1, Strepococcus mitis, Serratia
marcescens) with VAHS
None
14 Severe sepsis (pneumonia) MDS, secondary AML, PBSCTx
15 Septic shock, OPSI (sinusitis, Streptococcus pneumoniae) Post splenectomy
16 Septic shock (pneumonia, Staphylococcus aureus) Cystic fibrosis, re-double-lung transplantation, diabetes, liver cirrhosis
17 Septic shock (pneumonia, Streptococcus pneumoniae) Multiple myeloma, AL amyloidosis (cardiac, renal), autologous SCTx
4 months ago,
18 Septic shock (pneumonia) Septic granulomatosis
19 Septic shock, OPSI (chronic otitis, Streptococcus pneumoniae) Kidney transplantation, rapidly progressive GN, s/p acute rejection
3 weeks prior with subsequent rituximab treatment
20 Septic shock (colon perforation, Pseudomonas aeruginosa,
Acinetobacter baumanii, Klebsiella pneumonia)
Crohn’s disease, cachexia
21 Septic shock (pneumonia, Streptococcus pneumonia) COPD
22 Septic shock (acute liver failure due to HSV) Hysterectomy because of uterine myomas
23 Septic shock (MOF due to VZV) Type 2 Diabetes
AML = acute myeloid leukemia, COPD = chronic obstructive pulmonary disease, GN = glomerulonephritis, MDS = myelodysplastic syndrome, MOF = multiple
organ failure, OPSI = overwhelming post splenectomy infection, PBSCTx = peripheral blood stem cell transplantation, UIP = usual interstitial pneumonitis,
VAHS = virus-associated hemohagocytotic syndrome, VZV = varizella zoster virus.
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ences of TPE on DIC. Time courses of platelet counts be-
tween day −2 and day 6 around the first PE therapy were
plotted separately for non-survivors and survivors in
Figure 3. Platelet counts decreased significantly during the
first (p = 0.012) and second (p = 0.023) day following the
first TPE procedure, irrespective of outcome (p > 0.31). A
stabilisation or increase in platelet count on days 2 to 4
following TPE was observed in 5 out of 9 survivors (56%),
but only 1 out of 14 non-survivors (7%).
Effect of potential predictive parameters on outcome
Survivors and non-survivors did not differ significantly re-
garding age (p = 0.40), baseline C-reactive protein (p =
0.190), or baseline SOFA score (p = 0.553). The following
parameters showed slight differences between survivors
and non-survivors, however, without statistical significance:baseline procalcitonin (34 μg/l [IQR 19–74] vs. 13.6 μg/l
[IQR 2–109], p = 0.439, upper limit of normal 0.5 μg/l),
time from ICU admission to first TPE (1 day [IQR 0–2] vs.
1.5 days [IQR 0–11], p = 0.369), number of TPE sessions (3
[IQR 1–3] vs. 1.5 [IQR 1–2], p = 0.159), and volume ex-
changed per plasma volume (1600 ml [IQR 1400–2600] vs.
1000 ml [IQR 800–1600], p = 0.159). Four out of 9 patients
(44%) who survived and 6 out of 14 patients who died
(43%) had been treated with immunosuppressive drugs
before the development of severe sepsis. Co-morbidities
associated with immunosuppression (e.g. vasculitis, hemo-
phagocytosis, myelodysplastic syndrome, multiple mye-
loma, recent splenectomy, inflammatory bowel disease, or
organ transplantation) were common in survivors (55%)
and non-survivors (71%) without significant difference
(p = 0.657). Though not significant, septic shock mediated
by streptococci (known as streptococcal toxic shock















1 140 5 13 Yes No 4 No
2 381 12 54 No Yes 3 Yes
3 89 15 18 Yes Yes 5 No
4 86 17 25 Yes Yes 5 Yes
5 117 11 0,1 Yes Yes 5 No
6 293 11 34 Yes Yes 6 Yes
7 240 16 400 Yes Yes 5 No
8 58 15 94 Yes Yes 5 Yes
9 56 20 12.8 Yes Yes 5 Yes
10 220 4 0.6 Yes Yes 1 Yes
11 107 13 1.8 Yes Yes 4 No
12 102 18 47.8 Yes Yes 4 No
13 200 10 2,5 Yes No 1 No
14 108 7 0.1 Yes Yes 2 No
15 351 9 107 Yes Yes 5 Yes
16 67 11 182 Yes Yes 4 No
17 192 13 30.6 Yes Yes 5 Yes
18 335 11 37 Yes Yes 4 Yes
19 83 16 337 Yes Yes 5 No
20 50 17 3.6 Yes No 5 No
21 80 16 84.7 Yes Yes 5 No
22 283 16 13.7 Yes Yes 5 No
23 93 19 9.6 Yes Yes 6 No
ECMO = extracorporeal membrane oxygenation, FiO2 = fraction of inspired oxygen, ICU = intensive care unit, paO2 = arterial O2 partial pressure, PCT = procalcitonin,
RRT = renal replacement therapy, SOFA = sepsis-related organ failure assessment, ULN = upper limit of normal.
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than among non-survivors (6 out of 9 [67%] versus 4 out
of 14 [29%], p = 0.102).
Discussion
This retrospective observational study reports the single-
centre experience on the use of TPE as rescue therapy
in patients with severe sepsis or septic shock and subse-
quent MOF. Although we often regard RCTs as the
summit of evidence-based medicine [32], we should not
disregard the role of therapeutic experience in individual
patients. The importance of considering other study de-
signs, such as observational studies, in the challenging
intensive care unit environment has recently been
highlighted [32]. In that sense, our case series focuses on
a potential treatment option that has nearly been forgot-
ten during the last 10 years since Busund et al. published
the first and largest RCT supporting the use of TPE in
septic shock. This trial on 106 patients, 56% of whom
had septic shock, seemingly showed a survival benefit in
the TPE group which fell short of significance when per-
forming multiple logistic regression [10].Regrettably, we are still not sure whether TPE exerts any
beneficial contribution to the reversal of MOF. Although
there are hardly any contraindications of a this rather safe
rescue procedure in a near-fatal clinical situation, complica-
tions such as urticarial reactions, anaphylactoid reactions,
citrate-induced hypocalcemia, catheter-related trauma,
clotting, infection, or bleeding as well as transfusion-related
lung injury may occur in association with TPE and there-
fore need to be taken into account [33]. Although TPE
implicates significant costs (1267 Euro, i.e. approximately
1577 USD per TPE in Germany), alternative rescue modal-
ities such as adsorption techniques are likely to be even
more costly and lack the potential to replenish the organ-
ism with removed substances. This consideration and the
highly prevalent consumptive coagulopathy led us to use
FFP as replacement fluid. Membrane filtration was pre-
ferred over centrifugation technique because it was more
readily available. However, activation of complement and
leukocytes on the artificial membrane are potential disad-
vantages of the membrane based TPE [34]. Other authors
have used similar approaches. Stegmayr et al. performed
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Figure 1 Norepinephrine dose before, during and after first therapeutic plasma exchange (TPE) in non-survivors and survivors.
Norepinephrine doses as surrogate marker of hemodynamic instability are presented relating to the time of first TPE: 3 hours before initiation of
TPE (h-3), initiation of TPE (h0), 3 hours after TPE (h+3), 6 hours after TPE (h+6), 9 hours after TPE (h+9), 12 hours after TPE (h+12), and 24 hours
after TPE (h+24).
Table 3 Details of plasma exchange therapy
Patient BMI (kg/m2) Time ICU admission
to TPE (days)








1 24.9 0 2 (1,2) 3.70 1.6 Heparin M
2 22.4 1 4 (2,3,4,5) 3.57 4.1 Citrate M
3 17.9 2 1 (3) 2.30 1.1 Citrate M
4 21.6 0 1 (1) 3.17 0.8 Citrate M
5 24.2 8 1 (9) 3.85 0.9 Heparin M
6 15.1 7 3 (9,10,12) 2.07 1.5 Heparin M
7 26.3 0 3 (1,3,6) 4.41 1.8 None M
8 26.0 2 1 (3) 3.20 0.5 None M
9 22.0 2 3 (3,4,5) 2.60 1.9 Citrate M
10 22.0 1 3 (2,3,4) 3.30 3.3 Heparin M
11 29.3 25 2 (25,26) 4.26 0.4 None M
12 30.7 14 3 (14–16) 5.66 1.6 Heparin M
13 22.9 11 2 (11,13) 3.77 1.3 Heparin M
14 18.8 16 1 (16) 3.07 0.8 Heparin M
15 21.4 0 1 (1) 2.60 1.4 None M
16 20.0 2 2 (2,3) 2.15 2.8 Heparin M
17 22.5 1 2 (2,3) 3.05 1.6 Citrate M
18 24.2 0 3 (1,3,4) 3.87 2.6 Citrate M
19 31.2 1 1 (2) 4.38 0.6 None M
20 23.7 0 2 (1,2) 2.83 1.8 Heparin M
21 24.9 1 1 (2) 3.47 0.9 Citrate C
22 24.2 0 1 (1) 3.77 0.8 Citrate M
23 24.2 1 1 (2) 4.20 0.9 Citrate C
MI = body mass index, FFP = fresh frozen plasma, ICU = intensive care unit, PV = plasma volume,TPE = therapeutic plasmapheresis.
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Figure 3 Platelet count before and after first therapeutic plasma exchange (TPE) in non-survivors and survivors. Platelet counts as
surrogate marker of septic microangiopathy are presented relating to the time of first TPE: 1 day before initiation of TPE (d-1), day of TPE (d0),
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Figure 2 Net fluid balance before and after first therapeutic plasma exchange (TPE). Net fluid balances as surrogate marker of septic
vascular permeability are presented relating to the time of first TPE: 12 hours preceding TPE, hours 0 to 12 after TPE, and hours 12 to 24 after TPE.
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of sessions, FFP in cases of spontaneous bleeding, and
switched to a 5% albumin crystalloid solution after stabil-
isation or in case of depleted supply pool at the blood bank
[24]. Busund et al. used continuous flow plasmapheresis
and replaced plasma losses with FFP diluted with 5% albu-
min in a 1:1 ratio [10]. Reeves et al. used a membrane filtra-
tion technique and replaced plasma losses with FFP and a
4% albumin-electrolyte solution mixed in a 1:4 ratio [11].
Compared to other trials in the field of sepsis with
MOF, the morbidity in the current case series was very
high. The SOAP study on 1177 sepsis patients revealed a
mean baseline SOFA score of 6.5 and an ICU-mortality
of 27% [35]. The 330 patients with septic shock partici-
pating in the trial of Annane et al. displayed a SOFA
score of 11 and an ICU-mortality of 45% [36]. Our pa-
tients had a median SOFA score of 13 and a median
number of 5 failing organs during the ICU stay, resulting
in an overall mortality rate of 61%. Although this is
comparable to the mortality of patients with 4 or more
failing organs in the SOAP study [35], it remains re-
markable that three of our most severely ill patients
among the survivors of MOF had extraordinarily high
baseline SOFA scores of 15,17, and 20, respectively
[35,37]. Additionally, patients with advanced MOF often
suffer from conditions such as acidosis or bowel ische-
mia that per se cannot be reversed by TPE therapy. We
were, unfortunately, not able to reproduce the very low
mortality rates seen by Stegmayr et al. The 76 patients
in their retrospective study also suffered from multiple
organ failure (88% septic shock, most of them due to
streptococci), and the study was comparable to our case
series concerning the number of failed organs and TPE
procedures performed. However, disease severity was
probably lower (66 vs. 87% on renal replacement therapy;
72 vs. 96% on mechanical ventilation or ECMO) [24].
Despite a lack of convincing evidence, it is our impres-
sion that several of our patients might not have survived
MOF without TPE therapy. This assumption is mainly
based on the association of TPE and clinical improvement
in these selected cases. As suggested earlier [8] and pos-
sibly supported by our data, reversal of thrombocytopenia
might be one parameter to monitor TPE-associated im-
provement. Of note, early post-interventional declines of
thrombocyte counts are common [38] and due to loss of
platelets in the discarded plasma, filter thrombosis, and
hemodilution by infusion of relatively hyperoncotic re-
placement fluid [33]. Those transient changes should not
lead to premature TPE abandonment. Additionally, we
have – as others - observed severe septic cardiomyopathy
which rapidly and markedly improved after initiation of
TPE [21]. Contrary to our expectations and earlier reports
[39], vasopressor doses did not improve following TPE in
the overall analysis. However, a significantly reduced netfluid balance might - besides an improvement of oncotic
pressure by isovolemic protein substitution - indicate that
TPE could beneficially effect vascular permeability. In fact,
others have described a reversal of fluid shifts from the
extravascular compartment into the vessels as an early
sign of response even after a single TPE procedure [39].
Timely fluid shifts back into the vascular compartment to
achieve a negative fluid balance seem to have major prog-
nostic relevance in critically-ill patients with acute kidney
injury, since several studies have shown that fluid overload
in these patients is associated with increased mortality
[40,41]. Most interestingly, the endothelial angiopoietin-2-
Tie ligand-receptor system mediates vascular leakage in
sepsis [42], and elevated circulating angiopoietin-2 can be
effectively removed by plasma exchange [43].
A comparison of survivors and non-survivors of septic
shock might help in the decision when to consider rescue
TPE therapy in septic shock. Survivors were felt to be
younger, to display higher procalcitonin values, to present
at an earlier stage of MOF, to have more plasma volume
exchanged, and to receive TPE earlier, although this was
not significant due to small patient numbers. The latter
observation would be supported by earlier data suggesting
that earlier TPE might improve outcome, whereas PE per-
formed > 40 h after presentation is unlikely to be useful in
severe septic vasoplegia [14]. Additionally, the high preva-
lence of streptococcal toxic shock syndrome [44] among
survivors might indicate that this entity is particularly
amenable to TPE therapy.
We are aware of several important limitations of our
study: i) The small patient number and the retrospective
observational design are due to the fact that there is only a
small window of therapeutic opportunity in fulminant sep-
tic shock. Even at a university hospital the minority of such
patients are admitted in the very acute phase of over-
whelming sepsis where TPE might exert beneficial effects.
ii) We presented single-centre data because TPE is far from
being established as rescue therapy for septic shock even
between tertiary care hospitals, and TPE algorithms and
technologies used differ. iii) By analyzing consecutive TPEs
instituted for septic shock, we tried to minimize patient se-
lection bias. Still, TPE effects might have been underesti-
mated by including patients with irreversible multiple
organ failure. iv) Rescue TPE was instituted on the basis of
individual team decisions instead of pre-defined start and
stop criteria. Although not significant, those who died re-
ceived fewer TPEs. It is therefore possible that under-
dosing might have lead to underestimation of the efficacy
of rescue TPE. v) When analysing the hemodynamic effects
of TPE, we focused on the first TPE session, because 10 of
our patients (44%) received only one TPE procedure, and
we felt that there were too many confounders in this ex-
tremely ill patients during the following TPE sessions. This
might have underestimated the observed treatment effect.
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In conclusion, our retrospective observational data do nei-
ther support nor dismiss the role of TPE in fulminant sep-
tic shock on the basis of patient survival or surrogate
markers of organ failure. This is probably due to the small
patient number and the extremely high morbidity in the
current case series that possibly precluded clear TPE ef-
fects due to irreversible organ failure. However, TPE might
be able to ameliorate DIC and septic cardiomyopathy in
selected patients. Most importantly, TPE seems to de-
crease net fluid balance, possibly by improving vascular
permeability.
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